Snoeck E - Search Results

1

Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin.

Snoeck E, Hadziyannis SJ, Puoti C, Swain MG, Berg T, Marcellin P, Zarski JP, Jorga K, Zeuzem S. Snoeck E, et al. Liver Int. 2008 Jan;28(1):61-71. doi: 10.1111/j.1478-3231.2007.01603.x. Epub 2007 Oct 25. Liver Int. 2008. PMID: 17971091

2

Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.

Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Snoeck E, et al. Br J Clin Pharmacol. 2006 Dec;62(6):699-709. doi: 10.1111/j.1365-2125.2006.02741.x. Br J Clin Pharmacol. 2006. PMID: 17118125 Free PMC article.

3

Pharmacokinetics of ribavirin in patients with hepatitis C virus.

Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Wade JR, et al. Among authors: snoeck e. Br J Clin Pharmacol. 2006 Dec;62(6):710-4. doi: 10.1111/j.1365-2125.2006.02704.x. Br J Clin Pharmacol. 2006. PMID: 17118126 Free PMC article.

4

A comprehensive hepatitis C viral kinetic model explaining cure.

Snoeck E, Chanu P, Lavielle M, Jacqmin P, Jonsson EN, Jorga K, Goggin T, Grippo J, Jumbe NL, Frey N. Snoeck E, et al. Clin Pharmacol Ther. 2010 Jun;87(6):706-13. doi: 10.1038/clpt.2010.35. Epub 2010 May 12. Clin Pharmacol Ther. 2010. PMID: 20463660

5

Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C.

Brennan BJ, Lemenuel-Diot A, Snoeck E, McKenna M, Solsky J, Wat C, Mallalieu NL. Brennan BJ, et al. Among authors: snoeck e. Br J Clin Pharmacol. 2016 Apr;81(4):658-66. doi: 10.1111/bcp.12816. Epub 2016 Jan 8. Br J Clin Pharmacol. 2016. PMID: 26529640 Free PMC article.

6

The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV.

Opravil M, Rodriguez-Torres M, Rockstroh J, Snoeck E, Chung RT, Tietz A, Torriani FJ. Opravil M, et al. Among authors: snoeck e. HIV Clin Trials. 2012 Jan-Feb;13(1):33-45. doi: 10.1310/hct1301-033. HIV Clin Trials. 2012. PMID: 22306586 Clinical Trial.

7

Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules.

Snoeck E, Jacqmin P, Sargentini-Maier ML, Stockis A. Snoeck E, et al. Epilepsy Res. 2007 Sep;76(2-3):140-7. doi: 10.1016/j.eplepsyres.2007.07.011. Epub 2007 Sep 11. Epilepsy Res. 2007. PMID: 17851036

8

Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.

Jacqmin P, Snoeck E, van Schaick EA, Gieschke R, Pillai P, Steimer JL, Girard P. Jacqmin P, et al. Among authors: snoeck e. J Pharmacokinet Pharmacodyn. 2007 Feb;34(1):57-85. doi: 10.1007/s10928-006-9035-z. Epub 2006 Oct 19. J Pharmacokinet Pharmacodyn. 2007. PMID: 17051439

9

Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures.

Snoeck E, Stockis A. Snoeck E, et al. Epilepsy Res. 2007 Mar;73(3):284-91. doi: 10.1016/j.eplepsyres.2006.11.006. Epub 2006 Dec 29. Epilepsy Res. 2007. PMID: 17196793

10

Assessment of Maraviroc Exposure-Response Relationship at 48 Weeks in Treatment-Experienced HIV-1-Infected Patients in the MOTIVATE Studies.

Jacqmin P, Wade JR, Weatherley B, Snoeck E, Marshall S, McFadyen L. Jacqmin P, et al. Among authors: snoeck e. CPT Pharmacometrics Syst Pharmacol. 2013 Aug 14;2(8):e64. doi: 10.1038/psp.2013.42. CPT Pharmacometrics Syst Pharmacol. 2013. PMID: 23945605 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters